Skip to main content

NIH OKs embattled Boston biolab

Opponents fail to block construction of new complex, containing BSL 2, 3 and 4 laboratories

Written byJohn Dudley Miller
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
The National Institutes of Health (NIH) gave its final approval yesterday for Boston University (BU) to build a research complex containing Biosafety Level 2, 3 and 4 laboratories on its medical campus in the city?s South End/Roxbury neighborhood. Construction on the seven-story National Emerging Infectious Diseases Laboratories (NEIDL) will begin early this month and should be completed by August 2008, BU officials announced yesterday in a staff memo."We are proud to now be part of the national network of dedicated scientists and researchers who will use this state-of-the-art facility to safely find treatments and cures for some of the most dangerous infectious diseases that threaten Boston, the nation, and the world," the lab?s principal investigator, Mark Klempner, said in the memo, of which The Scientist obtained a copy."NIAID is pleased that another milestone has been accomplished in Boston University's effort to construct a National Biocontainment Laboratory to conduct important research on infectious diseases," Rona Hirschberg, senior program officer in the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Disease (NIAID), said in a statement released yesterday (February 2).The biolab project has been controversial since September 2003, when NIAID chose Boston over other competing sites and promised $128 million toward the lab?s $178 million projected cost.Opponents claimed that research on Ebola and other incurable diseases should not be conducted in a congested urban environment. In April 2004, 146 Massachusetts university professors sent a letter to the mayor and BU?s trustees, saying the risk of human error or terrorist attacks was too great to accept.Controversy over the plan intensified in January 2005 when the university and the city revealed that three BU workers working in a lower-security lab had infected themselves with a lethal strain of tularemia the previous year, eventually recovering.NEIDL proponents?including BU?s acting medical campus provost Thomas Moore --claimed the tularemia accident is irrelevant, because researchers in the new facility will work in air-sealed moon suits in Biosafety Level four (BSL-4) labs, the most highly-engineered and secure facilities. The mayor and most of City Council support the lab, according to Klare Allen, spokesperson for Roxbury?s Safety Net, one of the groups leading the opposition. NIH says the project will provide 660 permanent jobs with a total annual income of $33 million.Opponents appear to be accepting defeat. "They will construct a building," Allen admitted. However, she and Sheldon Krimsky, a professor at Tufts University in Boston who also opposes the lab, said they plan to shift their efforts, concentrating on ensuring the lab is operated as safely as possible. "We?re going to make sure they dot every ?i? and cross every ?t?," Allen said, adding that the Boston Public Health Commission is also considering a comprehensive set of new regulations to govern all 1,000 biology labs in the city.John Dudley Miller johnmiller@nasw.orgLinks within this article National Emerging Infectious Diseases Laboratories Record of Decision, Federal Register, February 2, 2006. https://a257.g.akamaitech.net/7/257/2422/01jan20061800/edocket.access.gpo.gov/2006/E6-1402.htmJ.D. Miller, "Sparks fly on Boston lab plan," The Scientist, May 5, 2004. https://www.the-scientist.com/article/display/22154/Stop the Bioterrorism Lab, Alternatives in Community and Environment https://www.ace-ej.org/BiolabWeb/biolab.htmlC. Kittredge, "BU BSL-4 lab faces more scrutiny," The Scientist, January 24, 2005. https://www.the-scientist.com/article/display/22576/"Thomas Moore named acting provost at BUMC," BU Bridge, March 19, 2004. https://www.bu.edu/bridge/archive/2004/03-19/moore.htmlS. Smith, "Bacterium infected 3 at BU biolab," Boston Globe, January 19, 2005 https://www.boston.com/news/local/articles/2005/01/19/bacterium_infected_3_at_bu_biolab/ Sheldon Krimsky https://www.tufts.edu/~skrimsky/bio.htm
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

Related articles background image
The Scientist Digest cover September 2026
September 2026

Multiplex Microscopy Becomes Easier with Encoded Antibodies

A new system that enables researchers to uniquely tag monoclonal antibodies for use in microscopy could help simplify complex imaging studies.

View this Issue
Rethinking ALS Biomarkers: From Discovery to Clinical Impact

Rethinking ALS Biomarkers: From Discovery to Clinical Impact

Alamar Biosciences logo
Best Practices for qPCR Assay Design and Optimization

Best Practices for qPCR Assay Design and Optimization

Bio-Rad
Beyond the Basics: Strategies for Single-Cell and Spatial Transcriptomics Analysis

Beyond the Basics: Strategies for Single-Cell and Spatial Transcriptomics Analysis

bioxcell
Scientist reviewing cellular and molecular data on a computer in a laboratory.

Building Translation-Ready Biomarkers with Connected Workflows

Danaher Logo

Products

Closeup image of a multi channel pipette dispensing pink liquid into a 96-well plate.

The ASSIST PLUS pipetting robot for affordable workflow automation

Integra Logo
Single cells in suspension

Rapidly isolate primary cells and make uniform single-cell suspensions with Corning® Cell Strainers

Corning logo
Abstract image representing cell membranes linked together.

CellBrite® Steady Membrane Stain: Cell surface staining built for real-time imaging

Biotium
sino biological logo

Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays